Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Olfactory Receptors: Location and Structure01:03

Olfactory Receptors: Location and Structure

The process of olfaction, also known as the sense of smell, is a sophisticated chemical response system. The specialized sensory neurons that facilitate this process, known as olfactory receptor neurons, are situated in an upper segment of the nasal cavity, known as the olfactory epithelium. Olfactory sensory neurons are bipolar, with their dendrites extending from the epithelium's apex into the mucus that lines the nasal cavity. Airborne molecules, when inhaled, traverse the olfactory...
Taste Buds and Receptors01:20

Taste Buds and Receptors

Gustation, or the sense of taste, is intrinsically linked to the anatomical structures located on the tongue. This organ's surface, along with the entirety of the oral cavity, is adorned with stratified squamous epithelium. Evident on the tongue are elevated structures known as papillae (singular = papilla), which house the mechanisms for the transduction of gustatory stimuli. Four distinct types of papillae exist, each identified by their unique morphological attributes: the circumvallate,...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Toxidromes: Clinical Features01:30

Toxidromes: Clinical Features

Toxidromes are specific patterns of symptoms resulting from toxic substance exposure. They help in the identification and treatment of poisoning. The symptoms of each toxidrome group indicate poisoning by a certain class of chemicals or drugs.1. Sympathomimetic: Stimulates the sympathetic nervous system. Symptoms include agitation, increased heart rate (HR), blood pressure (BP), respiratory rate (RR), temperature, and pupil size. Drugs like cocaine and amphetamines, along with tremors and...
Pyloric Obstruction01:11

Pyloric Obstruction

Pyloric obstruction, also referred to as gastric outlet obstruction, is a condition characterized by narrowing or blockage at the pylorus—the muscular valve regulating the flow of stomach contents into the duodenum. When this passage becomes impaired, the stomach cannot effectively empty its contents into the small intestine. This disruption leads to a range of gastrointestinal symptoms, including early satiety, bloating, epigastric pain, postprandial nausea, persistent vomiting, and...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Apixaban-Induced Tongue and Extremity Angioedema: A Case Report.

American journal of therapeutics·2026
Same author

Acetylation Variability in Elderly Tunisians: Implications for Isoniazid Dose Individualization.

Journal of clinical pharmacology·2026
Same author

Pioneering infection prevention and control education through simulation-based learning: impact on knowledge and skills in nursing students in Tunisia.

BMC nursing·2026
Same author

Atypical Presentation of Grade III Hand-Foot Syndrome in a Patient With Breast Cancer Receiving Docetaxel.

American journal of therapeutics·2026
Same author

Therapeutic Clozapine Monitoring Using Dose-Related Reference Range.

Therapeutic drug monitoring·2026
Same author

Epileptic child in remission: Ceiling effect of valproic acid.

La Tunisie medicale·2026
Same journal

The Challenges of Scientific Publishing: An Editor-In-Chief's Perspective.

Fundamental & clinical pharmacology·2026
Same journal

Glucagon-Like Peptide-1 Receptor Agonists in Cocaine Use Disorder: Clinical Observations and Underlying Mechanisms.

Fundamental & clinical pharmacology·2026
Same journal

TAAR1-Associated Trace Amines for Cutaneous Nociceptive Blockade in Rats.

Fundamental & clinical pharmacology·2026
Same journal

Synergistic Cardioprotection of Colchicine and Hyperbaric Oxygen Therapy in a Rat Model of Remote Ischemia-Reperfusion Injury.

Fundamental & clinical pharmacology·2026
Same journal

Probucol Exerts Anticancer Effects on SW480 Human Colorectal Cancer Cells via Modulation of Apoptosis- and Angiogenesis-Related Proteins.

Fundamental & clinical pharmacology·2026
Same journal

Nebivolol Protects the Thoracic and Abdominal Aorta and Their Perivascular Adipose Tissue From the Differential Detrimental Effects of Obesity.

Fundamental & clinical pharmacology·2026
See all related articles

Related Experiment Video

Updated: Jun 21, 2026

Studying the Effects of Inhaled Environmental Pollutants on Olfactory Function in Mice
04:00

Studying the Effects of Inhaled Environmental Pollutants on Olfactory Function in Mice

Published on: September 13, 2024

Recurrent dysosmia induced by pyrazinamide.

Sihem El Aïdli1, Sarrah Kastalli, Ahmed Zaïem

  • 1Centre National de Pharmacovigilance, Recueil et Analyse des Effets Indésirables, Tunis, Tunisia.

Fundamental & Clinical Pharmacology
|August 14, 2009
PubMed
Summary
This summary is machine-generated.

Pyrazinamide, a tuberculosis drug, can cause olfactory disorders. A case study shows reversible smell dysfunction after taking pyrazinamide, confirmed by rechallenge.

More Related Videos

Odorant-induced Responses Recorded from Olfactory Receptor Neurons using the Suction Pipette Technique
08:08

Odorant-induced Responses Recorded from Olfactory Receptor Neurons using the Suction Pipette Technique

Published on: April 5, 2012

Technique for Intranasal Administration of α-Synuclein Aggregates
04:49

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

Related Experiment Videos

Last Updated: Jun 21, 2026

Studying the Effects of Inhaled Environmental Pollutants on Olfactory Function in Mice
04:00

Studying the Effects of Inhaled Environmental Pollutants on Olfactory Function in Mice

Published on: September 13, 2024

Odorant-induced Responses Recorded from Olfactory Receptor Neurons using the Suction Pipette Technique
08:08

Odorant-induced Responses Recorded from Olfactory Receptor Neurons using the Suction Pipette Technique

Published on: April 5, 2012

Technique for Intranasal Administration of α-Synuclein Aggregates
04:49

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

Area of Science:

  • Pharmacology
  • Neuroscience
  • Toxicology

Background:

  • Pyrazinamide is a first-line antituberculosis medication.
  • Known adverse effects include hepatic toxicity, hyperuricemia, and digestive issues.
  • Rarely, taste and smell alterations have been linked to pyrazinamide, often in combination therapy.

Observation:

  • A case of reversible olfactory disorder associated with pyrazinamide monotherapy is presented.
  • The patient experienced a burning smell sensation 15 minutes after daily pyrazinamide intake.
  • Symptoms resolved upon drug discontinuation and reappeared upon rechallenge.

Findings:

  • Pyrazinamide monotherapy can induce reversible dysosmia (olfactory disorder).
  • The olfactory disturbance was characterized by a phantom smell of burning.
  • A positive rechallenge strongly suggests pyrazinamide as the causative agent.

Implications:

  • Highlights a rare but distinct side effect of pyrazinamide.
  • Emphasizes the importance of considering drug-induced olfactory dysfunction in differential diagnosis.
  • Suggests careful monitoring for sensory side effects during pyrazinamide treatment.